Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases

How to Cite

OrthoEvidence. Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases. ACE Report. 2020;9(10):7. Available from: https://myorthoevidene.com/AceReport/Report/12353

Study Type:Therapy

OE Level Evidence:1

Journal Level of Evidence:1

Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials.

J Am Acad Orthop Surg Glob Res Rev. 2020 Aug; 4(8): e20.00045.

Contributing Authors: H Al Farii A Frazer L Farahdel F AlFayyadh R Turcotte

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Four studies including 7320 patients with bone metastases from advanced cancer were included in this meta-analysis comparing the likelihood of pathological fracture. Sub-group analyses were performed by tumour origin (endodermal cancer, mesodermal cancer). Pooled results found the likelihood of pathological fracture to be significantly lower in the denosumab group compared to the zoledronic acid g...